Raptiva advisory committee
Executive Summary
Genentech/Xoma's Raptiva (efalizumab) will be reviewed by FDA's Dermatologic & Ophthalmic Drugs Advisory Committee Sept. 9 for the treatment of moderate-to-severe plaque psoriasis in adults. The companies recently submitted additional safety data to the BLA; the targeted T-cell modulator has a user fee goal date of Oct. 23. The meeting will be held at the Holiday Inn in Gaithersburg, Md., beginning at 8 a.m...
|
Genentech/Xoma's Raptiva (efalizumab) will be reviewed by FDA's Dermatologic & Ophthalmic Drugs Advisory Committee Sept. 9 for the treatment of moderate-to-severe plaque psoriasis in adults. The companies recently submitted additional safety data to the BLA; the targeted T-cell modulator has a user fee goal date of Oct. 23. The meeting will be held at the Holiday Inn in Gaithersburg, Md., beginning at 8 a.m.... |